Optiscan has been featured in a StockWire Special Report detailing the launch of its first formal Australian head and neck cancer imaging study, a 50-patient clinical program designed to generate FDA-quality data and support planned US regulatory submissions.

The article outlines the initiation of the Optiscan Head and Neck Cancer Study at St John of God Murdoch Hospital in Perth, led by head and neck cancer surgeon Dr Chady Sader. The study utilises Optiscan’s InVue® precision surgery and InForm™ digital pathology platforms to evaluate real-time intra-operative imaging in patients undergoing head and neck cancer surgery.

Importantly, the study activates two strategic partnerships established in 2025 — with Australian Clinical Labs for pathology analysis and Long Grove Pharmaceuticals for fluorescein sodium supply — demonstrating rapid progression from partnership agreement to clinical execution.

The report also highlights how the dual-device study design correlates real-time imaging with conventional histopathology, supporting regulatory evidence generation while advancing Optiscan’s oral cancer AI imaging algorithms. With head and neck cancers representing a significant global disease burden where surgical margin assessment is critical to outcomes, the study marks a key milestone in Optiscan’s clinical and regulatory strategy.

StockWire Special Report - Read the full article here.